Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016.
Bullous skin lesions in a patient with end-stage renal disease combined with myeloma and primary amyloidosis.
Jung JH et al. Kidney Res Clin Pract. 2016 Dec;35(4):263-264.
Crystalline podocytopathy and tubulopathy without overt glomerular proteinuria in a patient with multiple myeloma.
Lee EJ et al. Kidney Res Clin Pract. 2016 Dec;35(4):259-262.
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Cabrera César E et al. Arch Bronconeumol. 2016 Dec 8. pii: S0300-2896(16)30273-3. doi: 10.1016/j.arbres.2016.10.011. [Epub ahead of print].
Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Tiong IS et al. Leuk Lymphoma. 2016 Dec 8:1-9. [Epub ahead of print].
Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins.
Perazella MA et al. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2256-2259.
Intestinal Pneumatosis Associated with Tuberculosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Venkataramani V et al. Acta Haematol. 2016 Dec 7;137(1):51-54. [Epub ahead of print].
High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
Oiwa K et al. Anticancer Res. 2016 Dec;36(12):6655-6662.
Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
Keating M et al. BMJ Case Rep. 2016 Nov 29;2016. pii: bcr2016217000. doi: 10.1136/bcr-2016-217000.